Cite

HARVARD Citation

    Kuhle, J. et al. (2022). Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS. Multiple sclerosis. pp. 573-582. [Online]. 
  
Back to record